80 - Real-world experience of the 6 weekly schedule (q6w) of pembrolizumab in patients (pts) with metastatic non-small cell lung cancer (mNSCLC)
- Resource Type
- Abstract
- Source
- In
Lung Cancer March 2022 165 Supplement 1:S38-S38 - Subject
- Language
- ISSN
- 0169-5002